Last reviewed · How we verify
Betaferon, BAY86-5046
Betaferon is an immunomodulatory drug that works by inhibiting the production of interferon-gamma, a cytokine involved in the immune response.
Betaferon is an immunomodulatory drug that works by inhibiting the production of interferon-gamma, a cytokine involved in the immune response. Used for Relapsing-remitting multiple sclerosis.
At a glance
| Generic name | Betaferon, BAY86-5046 |
|---|---|
| Sponsor | Bayer |
| Drug class | Immunomodulator |
| Target | Interferon-gamma |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting interferon-gamma, Betaferon reduces the activation of immune cells and decreases the production of pro-inflammatory cytokines, leading to a decrease in inflammation and immune system activity. This mechanism of action is thought to be beneficial in the treatment of multiple sclerosis, a chronic autoimmune disease characterized by inflammation and demyelination in the central nervous system.
Approved indications
- Relapsing-remitting multiple sclerosis
Common side effects
- Injection site reactions
- Flu-like symptoms
- Headache
- Fatigue
- Nausea
Key clinical trials
- An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
- Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
- PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon
- EPID Multiple Sclerosis Pregnancy Study
- Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
- Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
- Betaferon Use in Children and Adolescents With Multiple Sclerosis
- Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betaferon, BAY86-5046 CI brief — competitive landscape report
- Betaferon, BAY86-5046 updates RSS · CI watch RSS
- Bayer portfolio CI